Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D2B6 | ISIN: US71678J2096 | Ticker-Symbol:
NASDAQ
01.11.24
20:17 Uhr
0,320 US-Dollar
-0,041
-11,46 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PETROS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
PETROS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur PETROS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.10.Petros Pharmaceuticals adjusts executive's salary and terms2
18.10.Petros Pharmaceuticals passt Gehalt und Vertragsbedingungen einer Führungskraft an1
17.10.Petros Pharmaceuticals ändert Bedingungen für Vorzugsaktien1
17.10.Petros Pharmaceuticals amends preferred stock terms2
17.10.Petros Pharmaceuticals, Inc. - 8-K, Current Report1
04.10.Petros Pharmaceuticals: Zwei Vorstandsmitglieder treten zurück2
04.10.Petros Pharmaceuticals sees two board members resign1
04.10.Petros Pharmaceuticals, Inc. - 8-K, Current Report3
19.09.Petros Pharmaceuticals sets date for 2024 annual meeting2
19.09.Petros Pharmaceuticals, Inc. - 8-K, Current Report3
11.09.Petros Pharmaceuticals reports high comprehension in drug app study2
11.09.Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA313Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)...
► Artikel lesen
03.09.Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference134NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development...
► Artikel lesen
21.08.Petros Pharmaceuticals stock hits 52-week low at $0.281
14.08.Petros Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
29.07.Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA296Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts...
► Artikel lesen
16.07.Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals' STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance237Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16,...
► Artikel lesen
17.06.EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says2
31.05.Petros Pharmaceuticals, Inc. - 10-K/A, Annual Report1
29.05.Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA OTC Switch284Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1